AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: diseases

newsFORsourcecompanycontentinformation1releasesmarket

Emilie Korchak Presented with a $20,000 Research Grant from Uplifting Athletes and the Foundation for Hao-Fountain Syndrome

Emilie Korchak from UConn Health was among 10 rare disease researchers awarded a grant at Uplifting Athletes' Young Investigator Draft on Jan. 31 at...

Professor Mohamed Shamji Assumes Presidency of EAACI as Congress 2026 Concludes in Istanbul

EAACI Congress 2026 concluded in Istanbul, welcoming 7,429 delegates from 110 countries and marking the start of Mohamed Shamji's Presidency.

New European initiative to accelerate drug discovery for cardiometabolic diseases

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).

Tevra Brands Launches “In Their Everywhere” Campaign as Pet Owners Prepare for Peak Tick Season

OMAHA, Neb., June 18, 2026 /PRNewswire/ -- Tevra Brands, a leader in innovative and affordable pet health solutions, proudly announces the launch of its new...

Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies

WATERTOWN, Mass. and CINCINNATI, June 18, 2026 (GLOBE NEWSWIRE) -- Constantiam Biosciences and Cincinnati Children's today announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3).

CenExel Appoints Bethany Sensenig as Chief Financial Officer

DRAPER, Utah, June 18, 2026 /PRNewswire/ -- CenExel, a leading, wholly owned clinical research site network, announced today the expansion of its leadership team...

SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies

SK pharmteco announces a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL) to support the advancement of novel therapeutic programs.

Health and Wellness Market Size to Hit $12.9 Trillion by 2031 Growing at a CAGR of 10.9%: Allied Market Research

Prevention and Curing Conditions On The Rise, Strong Demand for Beauty & Personal Care Products, Booming Wellness Tourism and Digital Health Nowadays to Accelerate the Growth of...

F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in...


MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units

JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital...

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders,Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building...

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers